The authors focused on men newly diagnosed with localized (non-metastatic) prostate cancer in 1995 - 2011 and treated
with radical prostatectomy, brachytherapy, radiation therapy, or primary androgen deprivation therapy (PADT).
Not exact matches
This new study, from a team led by Dr Yoshio Ohno of Tokyo Medical University, has shown that patients
with blood group O had a significantly decreased risk of cancer recurrence after
radical prostatectomy (RP).
Ga -68-BBN-RGD PET / CT detected 20 bone lesions in seven patients either
with primary prostate cancer or after
radical prostatectomy.
Two groups were analyzed: 126 localized intermediate risk CaP patients who had received image - guided radiation therapy (IGRT) treatments,
with a mean dose of 74.6 Gy; and 154 localized intermediate and high risk CaP patients who had undergone
radical prostatectomy (RP), which is the surgical removal of the entire prostate gland.
Patients
with prostate cancer underwent robotic assisted laparoscopic
radical prostatectomy, while the benign disease group underwent transurethral resection of prostate.
Management of low risk prostate cancer
with AS appears feasible and safe, yet most men in the U.S.
with low risk disease still undergo definitive therapies such as
radical prostatectomy, which carry the burden of urinary, bowel, and sexual dysfunction that can be avoided, or at the very least postponed,
with management on AS.
The present work focuses on patients
with physical damage, caused by surgery (
radical prostatectomy) for prostate cancer.
Dr. Kauffman specializes in the care of patients
with kidney and prostate cancers and provides expertise in both robot - assisted and open operative approaches, including partial or
radical nephrectomy and
radical prostatectomy.
Effect of Sulforaphane in Men
with Biochemical Recurrence after
Radical Prostatectomy.